FAS ordered the pharmaceutical manufacturer Grotex to pay 2 billion rubles for violation of competition.
According to Kommersant, the Antimonopoly Service issued a parallel order to the company operating under the Solofram brand due to the launch of the generic Emporix for the treatment of diabetes on the market.
The rights to its active ingredient (empagliflozin) in Russia until 2030 belong to the German pharmaceutical company Boehringer Ingelheim.